Cathepsin A inhibition attenuates myocardial infarction-induced heart failure on the functional and proteomic levels

Journal of Translational Medicine

Volumn 14, Issue 1, 2016, Pages

  Petrera, Agnese ^a   Gassenhuber, Johann ^b   Ruf, Sven ^b   Gunasekaran, Deepika ^a   Esser, Jennifer ^c   Shahinian, Jasmin Hasmik ^d   Hübschle, Thomas ^b   Rütten, Hartmut ^b   Sadowski, Thorsten ^b   Schilling, Oliver ^a,e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cardiovascular diseases; Drug therapy; Heart failure; Mouse model; Myocardial infarction

Indexed keywords

3 [[1 (2 FLUOROPHENYL) 5 METHOXY 1H PYRAZOLE 3 CARBONYL] AMINO] 3 O TOLYL PROPIONIC ACID; BRAIN NATRIURETIC PEPTIDE; ENZYME INHIBITOR; UNCLASSIFIED DRUG; CARBOXYPEPTIDASE C; PROTEINASE INHIBITOR; PROTEOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; FATTY ACID SYNTHESIS; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICULAR WEIGHT; HEART PROTECTION; IN VITRO STUDY; MALE; MOUSE; MUSCLE STRESS; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEOMICS; RAT; SURVIVAL RATE; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; HEART VENTRICLE; LIGATION; METABOLISM; MYOCARDIAL INFARCTION; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PEPTIDE MAPPING; PROCEDURES;

ANIMALS; CATHEPSIN A; CELL LINE; DISEASE MODELS, ANIMAL; HEART FAILURE; HEART VENTRICLES; LIGATION; MALE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; ORGAN SIZE; PEPTIDE MAPPING; PROTEASE INHIBITORS; PROTEOME; PROTEOMICS; RATS;

EID: 84971526204     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-016-0907-8     Document Type: Article

References (33)

1. Bonten EJ, Annunziata I, d'Azzo A. Lysosomal multienzyme complex: pros and cons of working together. Cell Mol Life Sci. 2014;71:2017-32.
2. Hiraiwa M. Cathepsin A/protective protein: an unusual lysosomal multifunctional protein. Cell Mol Life Sci. 1999;56:894-907.
3. Seyrantepe V, Hinek A, Peng J, Fedjaev M, Ernest S, Kadota Y, et al. Enzymatic activity of lysosomal carboxypeptidase (cathepsin) A is required for proper elastic fiber formation and inactivation of endothelin-1. Circulation. 2008;117:1973-81.
4. Petrera A, Lai ZW, Schilling O. Carboxyterminal protein processing in health and disease: key actors and emerging technologies. J Proteome Res. 2014;13:4497-504.
5. Ruf S, Buning C, Schreuder H, Linz W, Hubschle T, Linz D, et al. Inhibition of CatA: an emerging strategy for the treatment of heart failure. Future Med Chem. 2013;5:399-409.
6. Stanton LW, Garrard LJ, Damm D, Garrick BL, Lam A, Kapoun AM, et al. Altered patterns of gene expression in response to myocardial infarction. Circ Res. 2000;86:939-45.
7. Tsukamoto K, Mani DR, Shi J, Zhang S, Haagensen DE, Otsuka F, et al. Identification of apolipoprotein D as a cardioprotective gene using a mouse model of lethal atherosclerotic coronary artery disease. Proc Natl Acad Sci USA. 2013;110:17023-8.
8. Ruf S, Buning C, Schreuder H, Horstick G, Linz W, Olpp T, et al. Novel beta-amino acid derivatives as inhibitors of cathepsin A. J Med Chem. 2012;55:7636-49.
9. Tillner J LA, Paehler T, Lukacs Z, Ruf S, Sadowski T, Pinquier J-L, Ruetten H. Tolerability, safety and pharmacokinetics of the novel Cathepsin A inhibitor SAR164653 in healthy subjects. Clin Pharm Drug Dev. 2015; (in press).
10. Heineke J, Ruetten H, Willenbockel C, Gross SC, Naguib M, Schaefer A, et al. Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc. Proc Natl Acad Sci USA. 2005;102:1655-60.
11. Mendis S, Thygesen K, Kuulasmaa K, Giampaoli S, Mahonen M, Ngu Blackett K, et al. World Health Organization definition of myocardial infarction: 2008-09 revision. Int J Epidemiol. 2011;40:139-46.
12. Sun Y. Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc Res. 2009;81:482-90.
13. Shahinian H, Tholen S, Schilling O. Proteomic identification of protease cleavage sites: cell-biological and biomedical applications. Expert Rev Proteomics. 2013;10:421-33.
14. Itter G, Jung W, Juretschke P, Schoelkens BA, Linz W. A model of chronic heart failure in spontaneous hypertensive rats (SHR). Lab Anim. 2004;38:138-48.
15. Tholen S, Biniossek ML, Gessler AL, Muller S, Weisser J, Kizhakkedathu JN, et al. Contribution of cathepsin L to secretome composition and cleavage pattern of mouse embryonic fibroblasts. Biol Chem. 2011;392:961-71.
16. Tholen M, Wolanski J, Stolze B, Chiabudini M, Gajda M, Bronsert P, et al. Stress-resistant translation of cathepsin L mRNA in breast cancer progression. J Biol Chem. 2015;290:15758-69.
17. Lund EL, Hog A, Olsen MW, Hansen LT, Engelholm SA, Kristjansen PE. Differential regulation of VEGF, HIF1alpha and angiopoietin-1, -2 and -4 by hypoxia and ionizing radiation in human glioblastoma. Int J Cancer. 2004;108:833-8.
18. Patten RD, Aronovitz MJ, Einstein M, Lambert M, Pandian NG, Mendelsohn ME, et al. Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse. Clin Sci (Lond). 2003;104:109-18.
19. Maisel A. B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next? Circulation. 2002;105:2328-31.
20. Gaggin HK, Januzzi JL Jr. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. 2013;1832:2442-50.
21. Boersema PJ, Raijmakers R, Lemeer S, Mohammed S, Heck AJ. Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics. Nat Protoc. 2009;4:484-94.
22. Bronsert P, Weisser J, Biniossek ML, Kuehs M, Mayer B, Drendel V, et al. Impact of routinely employed procedures for tissue processing on the proteomic analysis of formalin-fixed paraffin-embedded tissue. Proteomics Clin Appl. 2014;8:796-804.
23. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98:5116-21.
24. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101:2981-8.
25. Fishbein MC, Wang T, Matijasevic M, Hong L, Apple FS. Myocardial tissue troponins T and I. An immunohistochemical study in experimental models of myocardial ischemia. Cardiovasc Pathol. 2003;12:65-71.
26. Zhao S, Wu H, Xia W, Chen X, Zhu S, Zhang S, et al. Periostin expression is upregulated and associated with myocardial fibrosis in human failing hearts. J Cardiol. 2014;63:373-8.
27. Vaananen HK, Syrjala H, Rahkila P, Vuori J, Melamies LM, Myllyla V, et al. Serum carbonic anhydrase III and myoglobin concentrations in acute myocardial infarction. Clin Chem. 1990;36:635-8.
28. Vuotikka P, Uusimaa P, Niemela M, Vaananen K, Vuori J, Peuhkurinen K. Serum myoglobin/carbonic anhydrase III ratio as a marker of reperfusion after myocardial infarction. Int J Cardiol. 2003;91:137-44.
29. Carter ND, Heath R, Jeffery S, Jackson MJ, Newham DJ, Edwards RH. Carbonic anhydrase III in Duchenne muscular dystrophy. Clin Chim Acta. 1983;133:201-8.
30. Razani B, Zhang H, Schulze PC, Schilling JD, Verbsky J, Lodhi IJ, et al. Fatty acid synthase modulates homeostatic responses to myocardial stress. J Biol Chem. 2011;286:30949-61.
31. Singh S, Manda SM, Sikder D, Birrer MJ, Rothermel BA, Garry DJ, et al. Calcineurin activates cytoglobin transcription in hypoxic myocytes. J Biol Chem. 2009;284:10409-21.
32. Bonavita F, Stefanelli C, Giordano E, Columbaro M, Facchini A, Bonafe F, et al. H9c2 cardiac myoblasts undergo apoptosis in a model of ischemia consisting of serum deprivation and hypoxia: inhibition by PMA. FEBS Lett. 2003;536:85-91.
33. Law CH, Li JM, Chou HC, Chen YH, Chan HL. Hyaluronic acid-dependent protection in H9C2 cardiomyocytes: a cell model of heart ischemia-reperfusion injury and treatment. Toxicology. 2013;303:54-71.